ABSTRACT
Objective To explore the efficacy of imatinib and dasatinib for treatment of newly diagnosed chronic my-elogenous leukemia chronic phase(CML-CP)patients. Methods Forty patients with CML-CP were selected in the Luoyang Central Hospital Affiliated to Zhengzhou University from January 2010 to June 2016. The patients were divided into imatinib group(n = 22)and dasatinib group(n = 18)according to the treatment method. The patients in imatinib group received ima-tinib orally for 1 year;the patients in dasatinib group received dasatinib orally for 1 year. The treatment response and curative effect of patients in the two groups were evaluated at 3,6 months after treatment;the aderverse reactions of patients in the two groups were evaluated at 12 months after treatment. Results The rate of optimal cytogenetic response of patients in imatinib group and dasatinib group was 45. 5％(10 / 22),55. 6％(10 / 18)at 3 months after treatment and 36. 4％(8 / 22),38. 9％(7 /18)at 6 months after treatment;the rate of optimal molecular response of patients in imatinib group and dasatinib group was 50. 0％(11 / 22),55. 6％(10 / 18)at 3 months after treatment and 31. 8％(7 / 22),38. 9％(7 / 18)at 6 months after treatment;the rate of failture to achieve a complete cytogenetic responses(CCyR)of patients in imatinib group and dasatinib group was 18. 2％(4 / 22),5. 6％(1 / 18)at 12 months after treatment;the rate of failure to achieve BCR-ABLIS≤1％ of patients in ima-tinib group and dasatinib group was 18. 2％(4 / 22),5. 6％(1 / 18)at 12 months after treatment. The rate of optimal cytogenetic response and optimal molecular response of patients in dasatinib group at 3,6 months after treatment were significantly higher than those in the imatinib group(P < 0. 05);the rate of failure to achieve a CCyR and BCR-ABLIS≤1％ of patients in dasat-inib group at 12 months after treatment were significantly lower than those in the imatinib group(P < 0. 05). The mutation rate of BCR-ABL kinase domain of patients in imatinib group and dasatinib group was 13. 6％(3 / 22)and 5. 6％(1 / 18)respective-ly;the mutation rate of BCR-ABL kinase domain of patients in imatinib group was significantly higher than that in the dasatinib group(P < 0. 05). Conclusion Compared with imatinib,dasatinib has better efficacy in treatment of CML-CP patients,and with lower mutation rate of BCR-ABL kinase domain. So,dasatinib is suitable for clinical use.